150 related articles for article (PubMed ID: 32744998)
1. A cross-sectional comparison of secondary polycythemia in testosterone-deficient men treated with nasal testosterone gel vs. intramuscular testosterone cypionate.
Best JC; Gonzalez D; Masterson TA; Blachman-Braun R; Pai R; Ramasamy R
Can Urol Assoc J; 2021 Feb; 15(2):E118-E122. PubMed ID: 32744998
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Hematocrit Change in Testosterone-deficient Men Treated With Intranasal Testosterone Gel vs Intramuscular Testosterone Cypionate: A Randomized Clinical Trial.
Rivero MJ; Ory J; Diaz P; Thirumavalavan N; Han S; Reis IM; Ramasamy R
J Urol; 2023 Jul; 210(1):162-170. PubMed ID: 37126399
[TBL] [Abstract][Full Text] [Related]
3. Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male.
Jones SD; Dukovac T; Sangkum P; Yafi FA; Hellstrom WJ
Sex Med Rev; 2015 Apr; 3(2):101-112. PubMed ID: 27784544
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate.
Choi EJ; Xu P; Barham D; El-Khatib FM; Yafi FA; Kavoussi PK
J Urol; 2022 Mar; 207(3):677-683. PubMed ID: 34694927
[TBL] [Abstract][Full Text] [Related]
5. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy.
Lundy SD; Parekh NV; Shoskes DA
J Sex Med; 2020 Jul; 17(7):1297-1303. PubMed ID: 32307242
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of secondary erythrocytosis in men receiving testosterone therapy A matched-cohort analysis of intranasal gel, injections, and pellets.
Reddy R; Diaz P; Blachman-Braun R; Loloi J; Rahman F; Ory J; Dullea A; Zucker I; Gonzalez DC; Kresch E; Ramasamy R
Can Urol Assoc J; 2023 Jul; 17(7):E202-E207. PubMed ID: 37068153
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Secondary Polycythemia in Hypogonadal Men Treated with Clomiphene Citrate versus Testosterone Replacement: A Multi-Institutional Study.
Wheeler KM; Smith RP; Kumar RA; Setia S; Costabile RA; Kavoussi PK
J Urol; 2017 Apr; 197(4):1127-1131. PubMed ID: 27984109
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Intratesticular Testosterone between Men Receiving Nasal, Intramuscular, and Subcutaneous Pellet Testosterone Therapy: Evaluation of Data from Two Single-Center Randomized Clinical Trials.
Diaz P; Reddy R; Blachman-Braun R; Zucker I; Dullea A; Gonzalez DC; Kresch E; Ramasamy R
World J Mens Health; 2023 Apr; 41(2):390-395. PubMed ID: 35791295
[TBL] [Abstract][Full Text] [Related]
9. Comparing Rates of Polycythemia in Hypogonadal Men Using Nasal Testosterone Gel Versus Intramuscular Testosterone: Update of a Randomized Clinical Trial.
Ory J; Diaz P; Rivero MJ; Clavijo RI; Thirumavalavan N; Blachman-Braun R; Loloi J; Bernstein A; Ramasamy R
Eur Urol Focus; 2023 Jan; 9(1):14-16. PubMed ID: 36109330
[TBL] [Abstract][Full Text] [Related]
10. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets.
Ip FF; di Pierro I; Brown R; Cunningham I; Handelsman DJ; Liu PY
Eur J Endocrinol; 2010 Feb; 162(2):385-90. PubMed ID: 19903801
[TBL] [Abstract][Full Text] [Related]
11. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
[TBL] [Abstract][Full Text] [Related]
12. Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy.
Ory J; Nackeeran S; Balaji NC; Hare JM; Ramasamy AR
J Urol; 2022 Jun; 207(6):1295-1301. PubMed ID: 35050717
[TBL] [Abstract][Full Text] [Related]
13. Natesto™ , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.
Rogol AD; Tkachenko N; Bryson N
Andrology; 2016 Jan; 4(1):46-54. PubMed ID: 26695758
[TBL] [Abstract][Full Text] [Related]
14. Association of subcutaneous testosterone pellet therapy with developing secondary polycythemia.
Rotker KL; Alavian M; Nelson B; Baird GL; Miner MM; Sigman M; Hwang K
Asian J Androl; 2018; 20(2):195-199. PubMed ID: 29205178
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials.
Nackeeran S; Kohn T; Gonzalez D; White J; Ory J; Ramasamy R
J Urol; 2022 Jan; 207(1):44-51. PubMed ID: 34445892
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of polycythaemia with different formulations of testosterone therapy in transmasculine individuals.
Nolan BJ; Leemaqz SY; Ooi O; Cundill P; Silberstein N; Locke P; Grossmann M; Zajac JD; Cheung AS
Intern Med J; 2021 Jun; 51(6):873-878. PubMed ID: 32237098
[TBL] [Abstract][Full Text] [Related]
17. Elevated Dihydrotestosterone is Associated with Testosterone Induced Erythrocytosis.
Aghazadeh M; Pastuszak AW; Johnson WG; McIntyre MG; Hsieh TM; Lipshultz LI
J Urol; 2015 Jul; 194(1):160-5. PubMed ID: 25596360
[TBL] [Abstract][Full Text] [Related]
18. Testosterone nasal gel (Natesto) for hypogonadism.
Med Lett Drugs Ther; 2015 May; 57(1468):73-4. PubMed ID: 25941957
[TBL] [Abstract][Full Text] [Related]
19. Male hypogonadism : an update on diagnosis and treatment.
Darby E; Anawalt BD
Treat Endocrinol; 2005; 4(5):293-309. PubMed ID: 16185098
[TBL] [Abstract][Full Text] [Related]
20. Body mass index in relation to semen quality and reproductive hormones in New Zealand men: a cross-sectional study in fertility clinics.
Macdonald AA; Stewart AW; Farquhar CM
Hum Reprod; 2013 Dec; 28(12):3178-87. PubMed ID: 24129611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
